Malarial Proteins may Improve Antimalarial Drugs

Two proteins are required for the deadliest malaria parasite to infect red blood cells and lyse cells after multiplication, says study funded by the National Institutes of Health. The new findings published in Science may provide researchers with potential new targets for drug development.

Plasmodium falciparum, the species of parasite that causes the most malaria deaths worldwide, has developed drug-resistance in five countries in Southeast Asia.

Malaria Parasite Protein: New Hope for Cisplatin-resistant Invasive Bladder Cancer

A protein derived from malarial parasite has been used to deliver cytotoxic compounds to chemotherapy-resistant invasive bladder cancer, reveals study.

‘Plasmepsin IX protein required for parasites to invade red blood cells and plasmepsin X required to exit infected cells. ’

In the current study, researchers sought to uncover the role of plasmepsins IX and X, two of the 10 types of plasmepsin proteins produced by P. falciparum for metabolic and other processes. They created malaria parasites that lacked plasmepsin IX or X under experimental conditions and compared them to those that had the two proteins.

The team found plasmepsin IX in rhoptries, specialized cell structures inside the parasite, which help it invade red blood cells. Parasites lacking plasmepsin IX had defective rhoptries. In addition, the team observed plasmepsin X in exonemes--small vesicles (balloon-like structures) that help malaria parasites exit infected cells. The team also discovered that plasmepsin X processes an important protein called SUB1. When deprived of plasmepsin X, the parasites couldn't process SUB1 and couldn't infect red blood cells or exit these cells after multiplying.

Fitter and Drug Resistant Strain of Malaria Parasite Threatens to Rise to Epidemic Proportions

Multidrug resistant strains of Plasmodium faliparum (malaria parasite) are increasing in numbers across Asia which requires urgent control and treatment.

The researchers also identified three experimental malaria drugs that may work by targeting plasmepsin X. One drug, called CWHM-117, has already been tested in a mouse model of malaria. The new findings may help researchers modify CWHM-117 to make it more effective. Furthermore, parasites lacking the plasmepsins could potentially be used to screen candidate drugs to identify additional anti-malaria compounds.

Source: Eurekalert